Moving from Hepatitis Discovery to Elimination: NIH Webinar Series on Research Advancing Hepatitis Elimination - Improving Early Detection of Hepatocellular Carcinoma (HCC): The Quest for New Biomarkers

NIH

7/8/21, 6:00 PM

America/New York GMT -4 summer

Description

Speakers

Banner

Link to the Event

Description

Fourth Webinar: July 8th, 3-5 pm ET
Improving Early Detection of Hepatocellular Carcinoma (HCC): The Quest for New Biomarkers
Hosted by the National Cancer Institute

Current guidelines (e.g. AASLD) recommend biannual (every 6 months) surveillance for hepatocellular carcinoma (HCC), usually using ultrasound (US) which may or may not include measuring the marker, AFP (alpha-fetoprotein). This is recommended for certain chronic liver diseases (e.g. HBV infected individuals) and also for individuals with cirrhosis. These surveillance recommendations achieve mixed results in their effectiveness for early detection of HCC. There is an unmet need to identify and implement more effective surveillance (e.g. imaging and biomarkers) for the early detection of HCC. This webinar will explore the challenges and opportunities for improving HCC surveillance.

Presentations:
Global Dimension of HCC and Epidemiology- Katherine McGlynn, National Cancer Institute (NCI)

HCC Surveillance Current Practices- Amit Singal, UT Southwestern Medical Center

Biomarkers for HCC- Anand Mehta, Medical University of South Carolina

Risk Assessment of HCC- Nabihah Tayob, Dana-Farber Cancer Institute and Harvard Medical School

Basic HCC Research: Mouse Models- Ray Chung, Massachusetts General Hospital

Previous registration necessary?

NO

YES

Simultaneous translation ?

YES

Will it be recorded?

NO

YES

Doug Lowy, Anna Lok, Lewis Roberts

Global Dimension of HCC and Epidemiology, HCC Surveillance Current Practices, Biomarkers for HCC, Risk Assessment of HCC, Basic HCC Research: Mouse Models

Inglês